Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia

Cancer

Volumn 117, Issue 21, 2011, Pages 4831-4868

  Wetzler, Meir ^a   Andrews, Chris ^a   Ford, Laurie A ^a   Tighe, Sheila ^a   Barcos, Maurice ^a   Sait, Sheila N J ^a   Block, Annemarie W ^a   Nowak, Norma J ^a,b   Baer, Maria R ^a,c   Wang, Eunice S ^a   Baumann, Heinz ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

acute myeloid leukemia; arsenic trioxide; phase 1; signal transducer and activator of transcription 3; treatment

Indexed keywords

ARSENIC TRIOXIDE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; STAT3 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ERUPTION; DRUG FATALITY; DRUG POTENTIATION; DRUG TARGETING; DRY SKIN; DYSPNEA; EPIGLOTTITIS; FEBRILE NEUTROPENIA; HUMAN; IN VIVO STUDY; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BRUISING; SKIN TOXICITY; URTICARIA;

EID: 80054805271     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26097     Document Type: Article

References (22)

1. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010; 28: 586-595.
2. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009; 361: 1249-1259.
3. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol. 2009; 27: 5397-5403.
4. Benekli M, Xia Z, Donohue KA, et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood. 2002; 99: 252-257.
5. Wetzler M, Brady MT, Tracy E, et al. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res. 2006; 12: 6817-6825. (Pubitemid 44876852)
6. Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res. 2004; 28: 909-919. (Pubitemid 38960752)
7. Baer MR, Pixley LA, Ford L, et al. High-dose cytarabine and idarubicin induction produces a high complete remission (CR) rate in previously untreated de novo acute myeloid leukemia (AML) patients (pts) <60 years old [abstract]. Blood. 2000; 96: 322a.
8. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006; 24: 2465-2471. (Pubitemid 46630623)
9. Vahter M,. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett. 2000; 112/113: 209-217. (Pubitemid 30138125)
10. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003; 21: 4642-4649. (Pubitemid 46594039)
11. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325-4336. (Pubitemid 35429670)
12. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2009; 106: 3342-3347.
13. Marnell LL, Garcia-Vargas GG, Chowdhury UK, et al. Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol. 2003; 16: 1507-1513. (Pubitemid 38049369)
14. Agusa T, Iwata H, Fujihara J, et al. Genetic polymorphisms in AS3MT and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol Appl Pharmacol. 2009; 236: 131-141.
15. Chung CJ, Hsueh YM, Bai CH, et al. Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer. Cancer Causes Control. 2009; 20: 1653-1661.
16. Porter KE, Basu A, Hubbard AE, et al. Association of genetic variation in cystathionine-beta-synthase and arsenic metabolism. Environ Res. 2010; 110: 580-587.
17. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89: 3354-3360.
18. Wetzler M, Earp JC, Brady MT, Keng MK, Jusko WJ,. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity-pharmacodynamic drug-drug interaction modeling. Clin Cancer Res. 2007; 13: 2261-2270. (Pubitemid 46649896)
19. Ghoshal S, Rao I, Earp JC, Jusko WJ, Wetzler M,. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemother Pharmacol. 2010; 66: 681-689.
20. Benekli M, Baumann H, Wetzler M,. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol. 2009; 27: 4422-4432.
21. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008; 453: 1072-1078. (Pubitemid 351871736)
22. Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008; 14: 1333-1342.